ProMIS NeurosciencesPMN +22.42%30 Market Cap is $120.08 Mil as of Jun. 30, 2026. GuruFocus rates PMN with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,428 Biotechnology companies, ProMIS Neurosciences ranks worse than 52.87% on this metric.
ProMIS Neurosciences's quarterly market cap
declined
from Sep. 2025 ($22.87 Mil) to Dec. 2025 ($14.69 Mil) but then
increased
from Dec. 2025 ($14.69 Mil) to Mar. 2026 ($113.89 Mil).
ProMIS Neurosciences's annual market cap
increased
from Dec. 2023 ($21.71 Mil) to Dec. 2024 ($30.99 Mil) but then
declined
from Dec. 2024 ($30.99 Mil) to Dec. 2025 ($14.69 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. ProMIS Neurosciences's Enterprise Value for Today is $54.17 Mil.
ProMIS Neurosciences (NAS:PMN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
ProMIS Neurosciences Market Cap Related Terms
ProMIS Neurosciences Market Cap Historical Data
* Premium members only.
The historical data trend for ProMIS Neurosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ProMIS Neurosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ProMIS Neurosciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ProMIS Neurosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where ProMIS Neurosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
ProMIS Neurosciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ProMIS Neurosciences (PMN) has a Market Cap of $120.08 Mil as of Jun. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ProMIS Neurosciences and its competitors. According to the industry distribution chart, ProMIS Neurosciences ranks #755 out of 1428 companies in the Biotechnology industry, placing it in the top 52.9%.
Is ProMIS Neurosciences' Market Cap too high?
ProMIS Neurosciences' current Market Cap is $120.08 Mil. The Biotechnology industry median Market Cap is 119.44. ProMIS Neurosciences' value of $120.08 Mil is 0.5% above this industry median. Based on the distribution chart, ProMIS Neurosciences ranks #755 out of 1428 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ProMIS Neurosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ProMIS Neurosciences' Market Cap compare to BMEA and ANIX?
According to the Biotechnology industry distribution chart, ProMIS Neurosciences ranks #755 out of 1428 companies for Market Cap. This places ProMIS Neurosciences in the lower half of its industry. The industry median Market Cap is 119.44. ProMIS Neurosciences' value of $120.08 Mil is 0.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.44, based on 1,428 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ProMIS Neurosciences's current Market Cap of $120.08 Mil is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on ProMIS Neurosciences and its competitors. For the Biotechnology industry, the median Market Cap is 119.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ProMIS Neurosciences's current Market Cap is $120.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProMIS Neurosciences stock overvalued right now?
ProMIS Neurosciences (PMN) has a current Market Cap of $120.08 Mil. The current Market Cap is $120.08 Mil and 0.5% above the Biotechnology industry median of 119.44. ProMIS Neurosciences' overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For ProMIS Neurosciences (PMN), the current Market Cap is $120.08 Mil as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
30GF Score
Get the complete analysis for PMN
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMN has been successfully added to your 
